Summit Therapeutics is a binary oncology bet: ivonescimab could disrupt Keytruda-sized markets, but failure to replicate China data globally could severely impair the stock.
Overview
Summit Therapeutics is a pre-commercial, clinical-stage oncology company whose valuation is almost entirely tied to ivonescimab, a potentially first-in-class PD-1/VEGF bispecific antibody licensed from Akeso. The company has no revenue or approved products, making the investment highly binary. Ivonescimab has shown compelling progression-free survival advantages versus Keytruda in China and targets enormous NSCLC and solid-tumor markets. Key catalysts include global Phase III readouts and the FDA PDUFA decision for EGFR-mutated NSCLC on November 14, 2026.